The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy

The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy for Resectable Pancreatic Cancer. A Multifactorial Analysis of Metabolic Dysfunction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07182136

Enrollment

200

Registered

2025-09-19

Start date

2015-01-01

Completion date

2025-01-01

Last updated

2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy

Keywords

pancreatic ductal adenocarcinoma, pancreaticoduodenectomy, hepatic steatosis, nonalcoholic fatty liver disease, exocrine insufficiency

Brief summary

We will use simple summaries, educational handouts, and discussions with doctors and nurses to explain this study. The study looks at patients with early-stage pancreatic cancer who undergo pancreaticoduodenectomy (Whipple surgery). We found that some patients develop fatty liver (non-alcoholic fatty liver disease, NAFLD) within six months after surgery, which can affect nutrition, blood sugar control, and long-term survival. To help patients and families understand, we will: 1. Provide clear written information sheets about the purpose of the study and its findings. 2. Use diagrams or plain-language explanations of terms like pancreatic exocrine function and fatty liver. 3. Share results with healthcare providers so they can guide patients in nutrition, enzyme replacement, diabetes monitoring, and follow-up care. 4. Offer contact information for the research team to answer questions.

Interventions

PROCEDUREPancreaticoduodenectomy

Retrospective study evaluating postoperative NAFLD and metabolic outcomes in patients with stage I-II pancreatic cancer after PD.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Adults with stage I-II pancreatic ductal adenocarcinoma. * Underwent curative-intent pancreaticoduodenectomy (conventional or pylorus-preserving). * Surgery between January 2015 and May 2023. * Complete clinical and imaging data available. * Survived at least 6 months postoperatively.

Exclusion criteria

* Preoperative hepatic steatosis * Incomplete clinical or imaging data * Death within 6 months after surgery

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative nonalcoholic fatty liver disease (NAFLD)	6 months after pancreaticoduodenectomy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026